Start › Rak prostaty › Teksas › Dallas
Badania kliniczne dla Rak prostaty w mieście Dallas, TX
36 badań dla Rak prostaty szuka uczestników w ośrodkach w mieście Dallas i okolicach (w promieniu ok. 30 mil). Otwórz badanie, aby zobaczyć kryteria kwalifikacji i dane kontaktowe zespołu badawczego.
Oficjalny tekst badania (angielski)
Rekrutujesz uczestników do badania? Wyróżnij je na górze tej strony – $99 za 30 dni →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RekrutacjaFaza 1/2
- UT Southwest Simmons Cancer Center, Dallas
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
RekrutacjaFaza 3
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
RekrutacjaFaza 2
- Parkland Memorial Hospital, Dallas
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
RekrutacjaFaza 2
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
DESTINY-PANTUMOUR04
RekrutacjaBadanie obserwacyjne
- Research Site, Dallas
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
RekrutacjaFaza 3
- Texas Oncology - DFW ( Site 8001), Dallas
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
RekrutacjaFaza 3
- University of Texas Southwestern Medical Center - Simmons Cancer Center, Dallas
- University of Texas Southwestern Medical Center - William P. Clements, Jr., University Hospital, Dallas
- University of Texas Southwestern Simmons Cancer Center - Redbird, Dallas
- i 2 więcej
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
RekrutacjaFaza 2/3
- Texas Oncology, Dallas
A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
RekrutacjaFaza 1
- Mary Crowley Cancer Research, Dallas
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
RekrutacjaFaza 1
- Texas Oncology - DFW (Sammons CC), Dallas
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
RekrutacjaFaza 3
- University of Texas Southwestern Medical Center, Dallas
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
RekrutacjaFaza 3
- Parkland Health & Hospital System ( Site 0069), Dallas
- UT Southwestern Medical Center ( Site 0039), Dallas
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
RekrutacjaFaza 3
- Urology Clinics of North Texas, Dallas
- University of Texas Southwestern Medical Center, Dallas
Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
RekrutacjaFaza 1
- SCRI at Mary Crowley, Dallas
A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
RekrutacjaFaza 3
- Urology Clinics Of North Texas, Dallas
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
RekrutacjaFaza 2
- University of Texas Southwestern Medical Center, Dallas
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
RekrutacjaFaza 1/2
- University of Texas Southwestern Medical Center, Dallas
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
RekrutacjaFaza 3
- Parkland Memorial Hospital, Dallas
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
RekrutacjaFaza 2
- University of Texas Southwestern Medical Center, Dallas
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RekrutacjaFaza 1
- Mary Crowley Cancer Research, Dallas
- University of Texas Southwestern Medical Center, Dallas
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
RekrutacjaFaza 3
- Dallas VA Medical Center, Dallas
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
RekrutacjaFaza 1
- Urology Clinics of North Texas, Dallas
Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER)
RekrutacjaFaza 2
- UT Southwestern Medical Center-Dallas, Dallas
Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance
RekrutacjaFaza 3
- UT Southwestern Medical Center, Dallas
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
RekrutacjaFaza 4
- Univ of Texas Southwest Med Center, Dallas
Outcomes of Focal Ablation for Prostate Cancer
RekrutacjaBadanie obserwacyjne
- UTSW, Dallas
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RekrutacjaFaza 3
- UT Southwestern Medical Center, Dallas
Study of AZD0754 in Participants With Metastatic Prostate Cancer
RekrutacjaFaza 1/2
- Research Site, Dallas
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
RekrutacjaFaza 1
- Mary Crowley Cancer Research, Dallas
- Baylor University Medical Center, Dallas
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
RekrutacjaFaza 1
- Urology Clinics of North Texas, Dallas
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
RekrutacjaFaza 4
- UT Southwestern Medical Center, Dallas
Non-significant Risk (NSR) Study of [68Ga]-PSMA-11 (Illuccix) as a BgRT BioGuide on RefleXion X1
RekrutacjaBadanie obserwacyjne
- Ut Southwestern Medical Center, Dallas
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
RekrutacjaFaza 1/2
- Research Site 120, Dallas
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekrutacjaBadanie obserwacyjne
- Massive Bio SYNERGY-AI site, Dallas
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
RekrutacjaFaza 3
- Parkland Memorial Hospital, Dallas
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Customized TULSA-PRO Ablation Registry
RekrutacjaBadanie obserwacyjne
- University of Texas Southwestern Medical Center, Dallas
Badania dla Rak prostaty w innych miastach
- New York City, NY103 badań
- Houston, TX76 badań
- Los Angeles, CA61 badań
- Boston, MA59 badań
- St. Louis, MO46 badań
- Chicago, IL45 badań
- San Francisco, CA45 badań
- Philadelphia, PA44 badań
- Baltimore, MD43 badań
- Nashville, TN42 badań
- Seattle, WA42 badań
- Washington, DC38 badań
Inne badania w mieście Dallas
- Rak piersi55 badań
- Niedrobnokomórkowy rak płuca52 badań
- Nowotwór przerzutowy42 badań
- Niewydolność serca42 badań
- Nowotwory (wszystkie typy)37 badań
- Rak jelita grubego i odbytnicy33 badań
- Otyłość30 badań
- Rak jajnika28 badań
- Rak pęcherza moczowego27 badań
- Rak płuc27 badań
- Rak endometrium24 badań
- Choroby układu sercowo-naczyniowego23 badań
Źródło: ClinicalTrials.gov, dane pobrane 5 paź 2026. Każde badanie ustala własne kryteria kwalifikacji; zespół badawczy decyduje, kto może wziąć udział.